Elan, FeRx, Lyotropic Therapeutics Inc. deal

ELN and FeRx will develop, manufacture and commercialize FeRx's MTC-DOX magnetic targeted carrier (MTC) formulation of doxorubicin, which is in U.S. Phase I/II testing to treat primary liver cancer. The product uses an external magnetic field to direct localized delivery and retention of doxorubicin particles linked to elemental iron MTC microparticles. FeRx will receive equity and milestone payments, and the companies will share development costs and revenues. ...